Top

Annals of Nuclear Medicine

Published in:

01-07-2014 | Original Article

Radiation safety of outpatient ¹⁷⁷Lu-octreotate radiopeptide therapy of neuroendocrine tumors

Authors: Phillipe J. Calais, J. Harvey Turner

Published in: Annals of Nuclear Medicine | Issue 6/2014

Abstract

Purpose

To demonstrate the safety of outpatient 7.8 GBq ¹⁷⁷Lu-DOTA-tyr³-octreotate radiopeptide therapy of neuroendocrine tumors by measurement of radiation exposures of hospital personnel, carers and members of the public.

Methods

Seventy-six patients with progressive, metastatic neuroendocrine tumors each received four cycles of prescribed activity of 7.8 GBq ¹⁷⁷Lu-octreotate at 8-week intervals, as an outpatient procedure. Cohorts comprising four patients were treated in one room, each patient remaining in hospital until radiation exposure from them was below the release limit of 25 μSv h⁻¹ at 1 m. On occasion, a single patient was treated in a single room. Radiation exposures of hospital staff and patient carers were monitored by personal dosimeter, and nearby areas monitored with a survey meter.

Results

Mean whole-body radiation exposures per therapy day ranged from 8 μSv (physicist) to 33 μSv (nurse), with exposures to personnel, carers and members of the public well within the limits recommended by the International Commission on Radiological Protection. Patients excreted a mean of 46 % of the total administered activity of ¹⁷⁷Lu-octreotate within 4 h of therapy.

Conclusion

Lutetium-177-octreotate radiopeptide therapy of neuroendocrine tumors can be safely performed as an outpatient treatment.

Kwekkeboom DJ, de Herder WW, Kam BL, van Eijck CH, van Essen M, Kooij PP, et al. Treatment with the radiolabeled somatostatin analog [177 Lu-DOTA 0, Tyr3]octreotate: toxicity, efficacy, and survival. J Clin Oncol. 2008;26:2124–30.PubMedCrossRef

Bodei L, Cremonesi M, Grana CM, Fazio N, Iodice S, Baio SM, et al. Peptide receptor radionuclide therapy with (1)(7)(7)Lu-DOTATATE: the IEO phase I-II study. Eur J Nucl Med Mol Imaging. 2011;38:2125–35.PubMedCrossRef

Bakker WH, Breeman WA, Kwekkeboom DJ, De Jong LC, Krenning EP. Practical aspects of peptide receptor radionuclide therapy with [¹⁷⁷Lu][DOTA0, Tyr3]octreotate. Q J Nucl Med Mol Imaging. 2006;50:265–71.PubMed

Claringbold PG, Brayshaw PA, Price RA, Turner JH. Phase II study of radiopeptide ¹⁷⁷Lu-octreotate and capecitabine therapy of progressive disseminated neuroendocrine tumours. Eur J Nucl Med Mol Imaging. 2011;38:302–11.PubMedCrossRef

Claringbold PG, Price RA, Turner JH. Phase I–II study of radiopeptide ¹⁷⁷Lu-octreotate in combination with capecitabine and temozolomide in advanced low-grade neuroendocrine tumors. Cancer Biother Radiopharm. 2012;27:561–9.PubMedCrossRef

Kwekkeboom DJ, Krenning EP, Lebtahi R, Komminoth P, Kos-Kudla B, de Herder WW, et al. ENETS Consensus Guidelines for the Standards of Care in Neuroendocrine Tumors: peptide receptor radionuclide therapy with radiolabeled somatostatin analogs. Neuroendocrinology. 2009;90:220–6.PubMedCrossRef

Turner NC, Strauss SJ, Sarker D, Gillmore R, Kirkwood A, Hackshaw A, et al. Chemotherapy with 5-fluorouracil, cisplatin and streptozocin for neuroendocrine tumours. Br J Cancer. 2010;102:1106–12.PubMedCentralPubMedCrossRef

Baum RP, Kulkarni HR, Carreras C. Peptides and receptors in image-guided therapy: theranostics for neuroendocrine neoplasms. Semin Nucl Med. 2012;42:190–207.PubMedCrossRef

Turner JH. Outpatient therapeutic nuclear oncology. Ann Nucl Med. 2012;26:289–97.PubMedCrossRef

10.

ARPANSA. Radiation protection in the medical applications of ionizing radiation. Melbourne: ARPANSA; 2008.

11.

ARPANSA. Safety guide for radiation protection in nuclear medicine. Melbourne: ARPANSA; 2008.

12.

ARPANSA. Discharge of patients undergoing treatment with radioactive substances, RPS4. Melbourne: ARPANSA; 2002.

13.

ICRP (2004) Release of patients after therapy with unsealed radionuclides. ICRP Publication 94. Ann ICRP. 2004;34(2)

14.

IAEA. Release of patients after therapy with unsealed radionuclides. Vienna: IAEA; 2004.

15.

IAEA. Release of patients after radionuclide therapy. Vienna: IAEA; 2009.

16.

De Decker M, Turner JH. Automated module radiolabeling of peptides and antibodies with gallium-68, lutetium-177 and iodine-131. Cancer Biother Radiopharm. 2012;27:72–6.PubMedCrossRef

17.

Kunikowska J, Krolicki L, Hubalewska-Dydejczyk A, Mikołajczak R, Sowa-Staszczak A, Pawlak D. Clinical Results of Radionuclide Therapy of Neuroendocrine Tumours with ⁹⁰Y-DOTATATE and Tandem ⁹⁰Y/¹⁷⁷Lu-DOTATATE: which is a better therapy option? Eur J Nucl Med Mol Imaging. 2011;38:1788–97.PubMedCentralPubMedCrossRef

18.

Government of Western Australia. Radiation safety (general) regulations 1983 schedule VIII (2008 amendment). Perth: State Law Publisher; 1983.

19.

IAEA. International basic safety standards for protection against ionizing radiation and for the safety of radiation sources. Vienna: IAEA; 1996.

20.

Hoefnagel CA, Clarke SE, Fischer M, Chatal JF, Lewington VJ, Nilsson S, et al. Radionuclide therapy practice and facilities in Europe. EANM Radionuclide Therapy Committee. Eur J Nucl Med. 1999;26:277–82.PubMedCrossRef

21.

Kuyvenhoven JD, Busemann Sokole E, van Rijk P, Clausen M, Jamar F, Slegers G, et al. A survey of guidelines in 27 EANM associated societies by the EANM Task Group on Quality Assurance and Standardisation. European Association of Nuclear Medicine. Eur J Nucl Med. 2000;27:BP31–44.PubMedCrossRef

22.

Higashi T, Kudo T, Kinuya S. Radioactive iodine (¹³¹I) therapy for differentiated thyroid cancer in Japan: current issues with historical review and future perspective. Ann Nucl Med. 2012;26:99–112.PubMedCrossRef

23.

Goldsmith SJ. The real cost of theoretic risk avoidance: the need to challenge unsubstantiated concerns about (¹³¹)I therapy. J Nucl Med. 2011;52:681–2.PubMedCrossRef

24.

Sisson JC, Freitas J, McDougall IR, et al. Radiation safety in the treatment of patients with thyroid diseases by radioiodine ¹³¹I: practice recommendations of the American Thyroid Association. Thyroid. 2011;21:335–46.PubMedCrossRef

25.

Calais PJ, Turner JH. Outpatient ¹³¹I-rituximab radioimmunotherapy for non-hodgkin lymphoma: a study in safety. Clin Nucl Med. 2012;37:732–7.PubMedCrossRef

26.

Calais PJ, Page AC, Turner JH. Management of fear of radiation exposure in carers of outpatients treated with iodine-131. Ann Nucl Med. 2012;26:508–14.PubMedCrossRef

27.

US Nuclear Regulatory Commission, Release of Patients Administered Radioactive Materials. Washington DC. US NRC 1997, Regulatory Guide 8.39.

Title: Radiation safety of outpatient 177Lu-octreotate radiopeptide therapy of neuroendocrine tumors
Authors: Phillipe J. Calais
J. Harvey Turner
Publication date: 01-07-2014
Publisher: Springer Japan
Published in: Annals of Nuclear Medicine / Issue 6/2014
Print ISSN: 0914-7187
Electronic ISSN: 1864-6433
DOI: https://doi.org/10.1007/s12149-014-0843-8

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Radiation safety of outpatient ¹⁷⁷Lu-octreotate radiopeptide therapy of neuroendocrine tumors

Abstract

Purpose

Methods

Results

Conclusion

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Purpose

Methods

Results

Conclusion

Please log in to get access to this content

Other articles of this Issue 6/2014

Reply to ‘Is it time to validate the prognostic role of F-18-FDG PET/CT scan in thymic epithelial tumors?’

Application of a medium-energy collimator for I-131 imaging after ablation treatment of differentiated thyroid cancer

Evaluating the possible role of 68Ga-citrate PET/CT in the characterization of indeterminate lung lesions

Evaluation of the bubble point test of a 0.22-μm membrane filter used for the sterilizing filtration of PET radiopharmaceuticals

Derivation of attenuation map for attenuation correction of PET data in the presence of nanoparticulate contrast agents using spectral CT imaging

Optimisation of reconstruction—reprojection-based motion correction for cardiac SPECT